WO2004106365A3 - Modulatory peptide motifs for inducing th1 or th2 immune response - Google Patents

Modulatory peptide motifs for inducing th1 or th2 immune response Download PDF

Info

Publication number
WO2004106365A3
WO2004106365A3 PCT/US2004/016779 US2004016779W WO2004106365A3 WO 2004106365 A3 WO2004106365 A3 WO 2004106365A3 US 2004016779 W US2004016779 W US 2004016779W WO 2004106365 A3 WO2004106365 A3 WO 2004106365A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducing
immune response
peptide motifs
modulatory peptide
modulatory
Prior art date
Application number
PCT/US2004/016779
Other languages
French (fr)
Other versions
WO2004106365A2 (en
Inventor
Bruno Guy
Tino Krell
Roger Sodoyer
Original Assignee
Aventis Pasteur Inc
Bruno Guy
Tino Krell
Roger Sodoyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Inc, Bruno Guy, Tino Krell, Roger Sodoyer filed Critical Aventis Pasteur Inc
Publication of WO2004106365A2 publication Critical patent/WO2004106365A2/en
Publication of WO2004106365A3 publication Critical patent/WO2004106365A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Abstract

The present invention relates to techniques for inducing either a TH1 or TH2-type immune response. Specific motifs may be added or deleted from antigens, thus inducing either a TH1- or TH2-type immune response against the antigen.
PCT/US2004/016779 2003-05-28 2004-05-27 Modulatory peptide motifs for inducing th1 or th2 immune response WO2004106365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47364203P 2003-05-28 2003-05-28
US60/473,642 2003-05-28

Publications (2)

Publication Number Publication Date
WO2004106365A2 WO2004106365A2 (en) 2004-12-09
WO2004106365A3 true WO2004106365A3 (en) 2005-06-23

Family

ID=33490624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016779 WO2004106365A2 (en) 2003-05-28 2004-05-27 Modulatory peptide motifs for inducing th1 or th2 immune response

Country Status (1)

Country Link
WO (1) WO2004106365A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
WO2002005845A1 (en) * 2000-07-05 2002-01-24 Merieux Oravax Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
WO2003031469A2 (en) * 2001-10-02 2003-04-17 Mologen Ag Means for improving immune response

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024810A1 (en) * 1999-10-05 2001-04-12 Epimmune Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
WO2002005845A1 (en) * 2000-07-05 2002-01-24 Merieux Oravax Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
WO2003031469A2 (en) * 2001-10-02 2003-04-17 Mologen Ag Means for improving immune response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JANKOVIC D ET AL: "Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways", TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 22, no. 8, 1 August 2001 (2001-08-01), pages 450 - 457, XP004273455, ISSN: 1471-4906 *
RAMMENSE H-G ET AL: "MHC LIGANDS AND PEPTIDE MOTIFS: FIRST LISTING", IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 41, 1995, pages 178 - 228, XP002922828, ISSN: 0093-7711 *
SANCHEZ V ET AL: "FORMULATIONS OF SINGLE OR MULTIPLE H. PYLORI ANTIGENS WITH DC CHOL ADJUVANT INDUCE PROTECTION BY THE SYSTEMIC ROUTE IN MICE OPTIMAL PROPHYLACTIC COMBINATIONS ARE DIFFERENT FROM THERAPEUTIC ONES", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, ELSEVIER SCIENCE B.V., AMSTERDAM, NL, vol. 30, no. 2, March 2001 (2001-03-01), pages 157 - 165, XP001041503, ISSN: 0928-8244 *
VANDERSPEK J C ET AL: "Maintenance of the hydrophobic face of the diphtheria toxin amphipathic transmembrane helix 1 is essential for the efficient delivery of the catalytic domain to the cytosol of target cells", PROTEIN ENGINEERING, vol. 7, no. 8, 1994, pages 985 - 989, XP002310212 *
ZHANG RENLI ET AL: "Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum", INFECTION AND IMMUNITY, vol. 69, no. 1, January 2001 (2001-01-01), pages 386 - 391, XP002310213, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2004106365A2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2002013857A3 (en) A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
WO2004030608A3 (en) Nanoemulsion vaccines
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2007028047A3 (en) Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
IS5329A (en) Antigen transport system where monoglyceride or diglyceride derivatives are adjuvant
NL300415I1 (en) Vaccine against antigens from bacteria
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DK1265633T3 (en) The vaccine adjuvant
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2001062283A3 (en) Mucosal adjuvant formulation
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
EP1344827A3 (en) Antifreeze proteins from basidiomycetes
WO2007016715A3 (en) Immune response inducing preparations
AU2770601A (en) Compositions for enhancing the immune response
AU2003294220A1 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
WO2007020520A3 (en) Antigenic peptides and their use
WO2004106365A3 (en) Modulatory peptide motifs for inducing th1 or th2 immune response
AU2003302234A8 (en) Immune response associated proteins
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
WO2002032455A3 (en) Vaccine
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
AU2002334631A8 (en) Immune response associated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase